AIDX
20/20 Biolabs Inc. Common Stock (AIDX)
Healthcare • NASDAQ • $1.37-0.72%
- Symbol
- AIDX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical Devices
- Price
- $1.37
- Daily Change
- -0.72%
- Market Cap
- $14.36M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $50.00
- 52W Low
- $1.32
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- N/A
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
Company websiteResearch AIDX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.